Oral News and Research

RSS

CTCA presents research on new cancer nutrition therapies at A.S.P.E.N. Clinical Nutrition Week

Several Cancer Treatment Centers of America clinicians presented research from studies evaluating new cancer nutrition techniques and therapies at the American Society for Parenteral and Enteral Nutrition Clinical Nutrition Week held in Long Beach, Calif., February 14-17, 2015. CTCA clinicians led a plenary session and an oral abstract presentation, and presented eight posters to Clinical Nutrition Week attendees.

18 Feb 2015

Eliglustat drug improves liver, spleen size and hemoglobin level in adults with Gaucher disease type 1

Among previously untreated adults with Gaucher disease type 1, a genetic disease in which there is improper metabolism due to a defect in an enzyme, treatment with the drug eliglustat resulted in significant improvements in liver and spleen size hemoglobin level, and platelet count, according to a study in the February 17 issue of JAMA.

18 Feb 2015

$Postmenopausal women susceptible to bone fractures may be at increased risk for gum disease$

Postmenopausal women susceptible to bone fractures may be at increased risk for gum disease

Postmenopausal women susceptible to bone fractures may also be a higher risk for gum disease, according to researchers at Case Western Reserve University School of Dental Medicine and Case/Cleveland Clinic Postmenopausal Health Collaboration.

18 Feb 2015

Innophos Holdings' net sales decrease 1% to $194 million in fourth quarter 2014

Innophos Holdings, Inc., a leading international producer of performance-critical and nutritional specialty ingredients, with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets, today announced its financial results for the fourth quarter and full year 2014.

18 Feb 2015

Transplantation conditioning choices impact on CML outcomes revealed

For chronic myeloid leukaemia patients in their first chronic phase, the optimal pretransplantation conditioning regimen may be cyclophosphamide combined with intravenous busulfan, research suggests.

17 Feb 2015

ASU to host inaugural meeting for brand new scientific society in Tempe, Arizona

Arizona State University will host a premiere opportunity to engage and mingle with luminaries in the burgeoning field of evolutionary medicine, a new interdisciplinary approach that is becoming an essential perspective in our view of disease, today's medical practice and the worldwide impact on public health as it hosts the Inaugural International Society for Evolution, Medicine & Public Health Meeting, March 19-21, 2015 in Tempe, Arizona.

17 Feb 2015

Medical practitioners rarely prescribe proper treatments for childhood diarrhea, pneumonia in rural India

Few health care providers in rural India know the correct treatments for childhood diarrhea and pneumonia - two leading killers of young children worldwide. But even when they do, they rarely prescribe them properly, according to a new Duke University study.

16 Feb 2015

Study: Ebola transmission from deceased patients may be possible

To determine how long Ebola virus could remain infectious in a body after death, National Institutes of Health scientists sampled deceased Ebola-infected monkeys and discovered the virus remained viable for at least seven days. They also detected non-infectious viral RNA for up to 70 days post-mortem. The study, published in Emerging Infectious Diseases, suggests that Ebola transmission from deceased individuals may be possible for an extended period of time following death, underscoring the importance of using safe practices for handling corpses.

15 Feb 2015

Risk of ovarian cancer increased with even short-term HRT use

There has been much uncertainty regarding the risk of cancer associated with taking hormone replacement therapy (HRT) for the menopause. An analysis of all available evidence published in The Lancet today shows that HRT, even when taken for only a few years, significantly increases the risk of developing the two most common types of ovarian cancer.

13 Feb 2015

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Jazz Pharmaceuticals plc announced today that researchers will present data on the use of defibrotide, an investigational medicine being studied in the United States (U.S.) for the treatment of hepatic veno-occlusive disease (VOD), a rare, potentially life-threatening, early complication in patients undergoing hematopoietic stem-cell transplantation (HSCT) therapy.

13 Feb 2015

Study shows how cannabidiol works within cells

A team of Stony Brook University researchers have identified fatty acid binding proteins (FABPs) as intracellular transporters for two ingredients in marijuana, THC and CBD (cannabidiol).

13 Feb 2015

Analytical strategies that support OSD formulation: A new whitepaper from Malvern Instruments

A new whitepaper from Malvern Panalytical provides detailed guidance on the analytical technologies that help to accelerate oral solid dosage (OSD) product formulation to a successful conclusion.

From Malvern Panalytical 12 Feb 2015

$Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer$

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

In a pivotal Phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer.

12 Feb 2015

Oral pathogen protects different tumor cells from being killed by immune cells

Bacteria that are commonly found in the mouth are often abundant in patients with colon cancer, but the potential role these microbes play in tumor development has not been clear. A study published by Cell Press February 18th in the journal Immunity reveals that the oral pathogen Fusobacterium nucleatum protects a variety of tumor cells from being killed by immune cells.

12 Feb 2015

Experts gather at Cardiology 2015 conference to discuss challenges in treating congenital heart disease

Many aspects of pediatric cardiology are relatively new to the discipline. Only recently have physicians been able to accurately diagnose and characterize the myriad congenital cardiovascular conditions that occur and begin to apply successful strategies for care. This week, an international group of more than 800 medical experts gather at the nation's largest pediatric cardiology conference to discuss challenges in treating congenital heart disease in the fetus, neonates, children and young adults.

12 Feb 2015

Experts to discuss challenges in CHD treatments at pediatric cardiology conference

12 Feb 2015

AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

AbbVie (NYSE: ABBV) submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for the company's investigational, all-oral, ribavirin (RBV) and interferon (IFN)-free, 12-week, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), dosed once daily.

12 Feb 2015

Cumberland initiates clinical development of Boxaban (ifetroban) oral capsule for AERD treatment

Cumberland Pharmaceuticals Inc. today announced an expansion of its pipeline with a new Phase II development program. The Company has initiated the clinical development of Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease (AERD).

11 Feb 2015

Study shows low-dose oral iron supplementation after blood donation reduces hemoglobin recovery time

Among blood donors with normal hemoglobin levels, low-dose oral iron supplementation, compared with no supplementation, reduced the time to recovery of the postdonation decrease in hemoglobin concentration in donors with low or higher levels of a marker of overall iron storage (ferritin), according to a study in the February 10 issue of JAMA.

11 Feb 2015

Creatine monohydrate fails to slow clinical progression of Parkinson's disease

Treatment with creatine monohydrate for at least 5 years for patients with early and treated Parkinson disease failed to slow clinical progression of the disease, compared with placebo, according to a study in the February 10 issue of JAMA.

11 Feb 2015

Oral News and Research

CTCA presents research on new cancer nutrition therapies at A.S.P.E.N. Clinical Nutrition Week

Eliglustat drug improves liver, spleen size and hemoglobin level in adults with Gaucher disease type 1

Postmenopausal women susceptible to bone fractures may be at increased risk for gum disease

Innophos Holdings' net sales decrease 1% to $194 million in fourth quarter 2014

Transplantation conditioning choices impact on CML outcomes revealed

ASU to host inaugural meeting for brand new scientific society in Tempe, Arizona

Medical practitioners rarely prescribe proper treatments for childhood diarrhea, pneumonia in rural India

Study: Ebola transmission from deceased patients may be possible

Risk of ovarian cancer increased with even short-term HRT use

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Study shows how cannabidiol works within cells

Analytical strategies that support OSD formulation: A new whitepaper from Malvern Instruments

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

Oral pathogen protects different tumor cells from being killed by immune cells

Experts gather at Cardiology 2015 conference to discuss challenges in treating congenital heart disease

Experts to discuss challenges in CHD treatments at pediatric cardiology conference

AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

Cumberland initiates clinical development of Boxaban (ifetroban) oral capsule for AERD treatment

Study shows low-dose oral iron supplementation after blood donation reduces hemoglobin recovery time

Creatine monohydrate fails to slow clinical progression of Parkinson's disease

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News